At a glance
ClinicalIndex Comparison RecordN/ACompleted· 16 enrolled
Drug / intervention
Tenofovir + emtricitabine + raltegravir.drug
Likely dose
Tenofovir + emtricitabine + raltegravir. 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Study to Examine the Characteristics of HIV Decay Following Introduction of Combination Antiretroviral Therapy Including Raltegravir During Primary and Chronic HIV Infection
In Brief
A clinical study evaluating Tenofovir + emtricitabine + raltegravir. for HIV Infection. Completed, enrolled 16 participants across 4 sites.
Detailed Summary
The purpose of this study is to measure the decay characteristics of HIV in the blood of patients after taking a combination of anti-HIV drugs, which includes a new class of anti-HIV drug, an integrase inhibitor. This study explores how this new combination of therapy reduces virus in various compartments of the body and immune system.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infection
CountriesAustralia
CollaboratorsMerck Sharp & Dohme LLC
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
First PostedMar 2008
Primary CompletionMar 2011
Study CompletionJun 2011
TodayJul 2026
First PostedMar 24, 2008
Enrollment StartMar 1, 2008
Primary CompletionMar 1, 2011
Study CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 18.3 years ago
Interventions
Tenofovir + emtricitabine + raltegravir.drug
TDF 300mg once daily + FTC 200mg once daily + RAL 400mg twice daily.